Capricor Therapeutics Inc vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| CAPR | LLY | |
|---|---|---|
| Market Cap | $517.44 million | $1.06 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | — | $26.71 billion |
LLY leads on 1 of 1 size & scale factors.
Valuation
| CAPR | LLY | |
|---|---|---|
| P/E Ratio | — | 39.77 |
| Price / Book | 2.10 | 31.17 |
| Price / Sales | — | 13.26 |
CAPR leads on 1 of 1 valuation factors.
Profitability
| CAPR | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | — | 78.84% |
CAPR and LLY split the profitability factors evenly.
Dividend
| CAPR | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
CAPR and LLY split the dividend factors evenly.
Risk & Sentiment
| CAPR | LLY | |
|---|---|---|
| Short Interest | 2.65% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: CAPR overview, CAPR financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.